06256 - 2 Pages - 6 Hrs
ltdprinwival
w.3_obstract_template.docxCognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Aman, Michael G ; Hollway, Jill A; McDougle, Christopher J; Scahill, Lawrence ; Tierney, Elaine ; et al. Journal of Child and Adolescent Psychopharmacology ; New Rochelle Vol. 18, Iss. 3, (Jun 2008): 227-36.DOI:10.1089/cap.2007.0133
Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Aman, Michael G; Hollway, Jill A; McDougle, Christopher J; Scahill, Lawrence; Tierney, Elaine; et al.Journal of Child and Adolescent Psychopharmacology; New Rochelle Vol. 18, Iss. 3, (Jun 2008): 227-36.DOI:10.1089/cap.2007.0133
Abstract
Objective: The objective of this research was to explore the effects of risperidone on cognitive processes in children with autism and irritable behavior.
Method: Thirty-eight children, ages 5-17 years with autism and severe behavioral disturbance, were randomly assigned to risperidone (0.5 to 3.5 mg/day) or placebo for 8 weeks. This sample of 38 was a subset of 101 subjects who participated in the clinical trial; 63 were unable to perform the cognitive tasks. A double-blind placebo-controlled parallel groups design was used. Dependent measures included tests of sustained attention, verbal learning, hand-eye coordination, and spatial memory assessed before, during, and after the 8-week treatment. Changes in performance were compared by repeated measures ANOVA.
Results: Twenty-nine boys and 9 girls with autism and severe behavioral disturbance and a mental age of 18 months or greater completed the cognitive part of the study. No decline in performance occurred with risperidone. Performance on a cancellation task (number of correct detections) and a verbal learning task (word recognition) was better on risperidone than on placebo (without correction for multiplicity). Equivocal improvement also occurred on a spatial memory task. There were no significant differences between treatment conditions on the Purdue Pegboard (hand-eye coordination) task or the Analog Classroom Task (timed math test).
Conclusion: Risperidone given to children with autism at doses up to 3.5 mg for up to 8 weeks appears to have no detrimental effect on cognitive performance. [PUBLICTION ABSTRACT]
Details
Subject
Child psychology; Pharmacology; Autism; Behavior disorders; Cognition & reasoning
MeSH
Adolescent, Autistic Disorder -- psychology, Child, Child Behavior Disorders -- drug therapy, Child Behavior Disorders -- psychology, Child, Preschool, Cognition -- physiology, Cognition Disorders -- chemically induced, Cognition Disorders -- psychology, Double-Blind Method, Female, Humans, Irritable Mood -- physiology, Male, Psychomotor Performance -- drug effects, Psychomotor Performance -- physiology, Risperidone -- adverse effects, Risperidone -- pharmacology, Autistic Disorder -- drug therapy (major), Cognition -- drug effects (major), Irritable Mood -- drug effects (major), Risperidone -- therapeutic use (major)
Title
Cognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Author
Aman, Michael G; Hollway, Jill A; McDougle, Christopher J; Scahill, Lawrence; Tierney, Elaine; McCracken, James T; Arnold, L Eugene; Vitiello, Benedetto; Ritz, Louise; Gavaletz, Allison; Cronin, Pegeen; Swiezy, Naomi; Wheeler, Courtney; Koenig, Kathleen; Ghuman, Jaswinder K; Posey, David J
Journal of Child and Adolescent Psychopharmacology; New Rochelle
Volume
18
Issue
3
Pages
227-36
Publication year
2008
Publication date
Jun 2008
Mary Ann Liebert, Inc.
Place of publication
New Rochelle
Country of publication
United States, New Rochelle
Publication subject
ISSN
10445463
Source type
Scholarly Journals
Language of publication
English
Document type
Comparative Study
DOI
http://dx.doi.org.proxy-library.ashford.edu/10.1089/cap.2007.0133
Accession number
18582177
ProQuest document ID
204609296
Document URL
https://search-proquest-com.proxy-library.ashford.edu/docview/204609296?accountid=32521
Copyright
(©) © 2008 Mary Ann Liebert, Inc.
Last updated
2014-03-19
Database
ProQuest Central
References:
· Aman, M. G. , Hollway, J. A. , Leone, S. , Masty, J. , Nash, P. , & Arnold, L. E. Effects of risperidone on cognitive-motor perfor-mance and motor movements in chronically medicated chil-dren. Res Dev Disabil. (in press).
· 2.
Pandina, G. J. , Bilder, R. , Harvey, P. D. , & Aman, M. G. (2007). Risperidone and cognitive function in children with dis-ruptive behavior disorders. Biol Psychiatry, 62, 226-234, 2007.
The Influence of Risperidone on Attentional Functions in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Co-Morbid Disruptive Behavior Disorder
Günther, Thomas; Herpertz-Dahlmann, Beate; Jolles, Jellemer; Konrad, Kerstin.Journal of Child and Adolescent Psychopharmacology; New Rochelle Vol. 16, Iss. 6, (Dec 2006): 725-35.
Cited by (11) References (68)
· Full text - PDF (90 KB)
· 4.
Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children with Pervasive Developmental Disorders: APilot Study
Troost, Pieter W; Mark-Peter Steenhuis; Tuynman-Qua, Hanneke G; Kalverdijk, Luuk J; Buitelaar, Jan K; et al.Journal of Child and Adolescent Psychopharmacology; New Rochelle Vol. 16, Iss. 5, (Oct 2006): 611-9.
Cited by (63) References (37)
· Full text - PDF (113 KB)
· 5.
Adverse Effects of Risperidone on Spatial Working Memory First-Episode Schizophrenia
Reilly, James L; Harris, Margret S H; Keshavan, Matcheri S; Sweeney, John A.Archives of General Psychiatry; Chicago Vol. 63, Iss. 11, (Nov 2006): 1189-97.
Cited by (79) References (68)
· 6.
Acute and Long-Term Safety and Tolerability of Risperidone in Children with Autism
Aman, Michael G; L. Eugene Arnold, M.D; McDougle, Christopher J; Vitiello, Benedetto; Scahill, Lawrence; et al.Journal of Child and Adolescent Psychopharmacology; New Rochelle Vol. 15, Iss. 6, (Dec 2005): 869-84.
Cited by (106) References (25)
· Full text - PDF (133 KB)
· 7.
On the trail of a cognitive enhancer for the treatment of schizophrenia.
Stip, Emmanuel; Chouinard, Sylvie; Boulay, Luc Jean; National Library of Medicine.Progress in neuro-psychopharmacology & biological psychiatry Vol. 29, Iss. 2, (February 2005): 219-232.
· 8.
The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia
McGurk, Susan R; Carter, Cameron; Goldman, Robert; Green, Michael F; et al.The American Journal of Psychiatry; Washington Vol. 162, Iss. 5, (May 2005): 1013-6.
Cited by (38) References (24)
· 9.
Rate-decreasing effects of the atypical neuroleptic risperidone attenuated by conditions of reinforcement in a woman with mental retardation
Yoo, J Helen; Williams, Dean C; Napolitano, Deborah A; Peyton, Robert T; et al.Journal of Applied Behavior Analysis; Malden Vol. 36, Iss. 2, (Summer 2003): 245-8.
Cited by (14) References (4)
· 10.
SPSS. (2003). SPSS 13.0 for Windows. Chicago: SPSS, 2003.
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder
Bilder, Robert M; Goldman, Robert S; Volavka, Jan; Pal Czobor; et al.The American Journal of Psychiatry; Washington Vol. 159, Iss. 6, (Jun 2002): 1018-28.
Cited by (382)
· 12.
Risperidone in children with autism and serious behavioral problems
McCracken, James T, MD; McGough, James, MD; Shah, Bhavik, MD; Cronin, Pegeen, PhD; Hong, Daniel, MA; et al.The New England Journal of Medicine; Boston Vol. 347, Iss. 5, (Aug 1, 2002): 314-321.
Cited by (803) References (25)
· Full text - PDF (114 KB)
· 13.
Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism
Scahill, Larry; McCracken, James; McDougle, Christopher J; Aman, Michael; Arnold, L Eugene; et al.Journal of Child and Adolescent Psychopharmacology; New Rochelle Vol. 11, Iss. 4, (Dec 2001): 377-88.
Cited by (37) References (23)
· Full text - PDF (166 KB)
· 14.
Assessment in Multisite Randomized Clinical Trials of Patients with Autistic Disorder: The Autism RUPP Network
Arnold, L Eugene; Aman, Michael G; Martin, Andres; Collier-Crespin, Angie; Vitiello, Benedetto; et al.Journal of Autism and Developmental Disorders; New York Vol. 30, Iss. 2, (Apr 2000): 99-111.
Cited by (82)
· Full text - PDF (74 KB)
· 15.
Practitioner's guide to psychoactice drugs for children and adolescents
Walter, Garry.Australian and New Zealand Journal of Psychiatry; Oxford Vol. 33, Iss. 6, (Dec 1999): 965.
· 16.
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-anaylsis
Keefe, Richard S E; Silva, Susan G; Perkins, Diana O; Lieberman, Jeffrey A.Schizophrenia Bulletin; Oxford Vol. 25, Iss. 2, (1999): 201-22.
Cited by (538) References (108)
· 17.
(1999). Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res. 35:S51-S60, 1999.
Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay.
Keefe, R S; Lees-Roitman, S E; Dupre, R L; National Library of Medicine.Schizophrenia research Vol. 26, Iss. 1, (July 25, 1997): 9-14.
· 19.
Delis, D. C. , Kramer, J. H. , Kaplan, E. , Ober, B. A. , & Fridlund, A. J. (1994). California Verbal Learning Test-Children's version. San Antonio, TX: Psychological Corporation.
Cited by (561)
· 20.
American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, D.C.: American Psychiatric Association, 1994.
· Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders.
Lord, C; Rutter, M; Le Couteur, A; National Library of Medicine.Journal of autism and developmental disorders Vol. 24, Iss. 5, (October 1994): 659-685.
· 22.
Wilkinson, G. S. (1993). Wide Range Achievement Test—Third Edition. Administration Manual. Wilmington DE: Wide Range, Inc, 1993.
Practitioner's guide to psychoactive drugs for children and adolescents
Werry, John S (Ed); Aman, Michael G (Ed).Practitioner's guide to psychoactive drugs for children and adolescents. Chapter xxxi, 440 Pages. New York, NY, US: Plenum Medical Book Co/Plenum Publishing Corp, 1993.
· 24.
Methylphenidate and thioridazine in the treatment of intellectually subaverage children: effects on cognitive-motor performance.
Aman, M G; Marks, R E; Turbott, S H; Wilsher, C P; Merry, S N; et al.Journal of the American Academy of Child and Adolescent Psychiatry Vol. 30, Iss. 5, (September 1991): 816-824.
· 25.
Efficacy of methylphenidate among mentally retarded children with attention deficit hyperactivity disorder.
Handen, B L; Breaux, A M; Gosling, A; Ploof, D L; Feldman, H; et al.Pediatrics Vol. 86, Iss. 6, (December 1990): 922-930.
· 26.
National Institute of Mental Health. (1985). CGI (Clinical Global Im-pressions Scale). Psychopharmacol Bull. 21:839-844, 1985.
Aberrant Behavior Checklist (ABC)
Aman, Michael G; Singh, Nirbhay N; Stewart, Alistair W; Field, Carolyn J.(1985).
· 28.
Drugs and learning in mentally retarded persons
Anan, Michael G.Advances in Human Psychopharmacology Vol. 3, (1984): 121-163.
· 29.
Dunn, L. M., & Dunn, L. M Peabody Picture Vocabulary Test-Revised American Guidance Service Circle Pines, MN 1981
Cited by (2825)
· 30.
DESIGN AND ANALYSIS - A RESEARCHER'S HANDBOOK
KEPPEL, G. (1973).
· 31.
(1968). Purdue Pegboard Examiner Manual. Chicago: Science Research Associates, 1968.
32. The Purdue pegboard; norms and studies of reliability and validity.
TIFFIN, J; ASHER, E J; National Library of Medicine.The Journal of applied psychology Vol. 32, Iss. 3, (June 1948): 234-247.
· The Purdue pegboard; norms and studies of reliability and validity.
TIFFIN, J; ASHER, E J; National Library of Medicine.The Journal of applied psychology Vol. 32, Iss. 3, (June 1948): 234-247.
· Details
